JNJ ▲ +0.9% - Johnson & Johnson
$JNJ - New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
12-OCT-2026 04:05 PM ET
Share this post
More filings for $JNJ
JNJ ▲ +0.1% - Johnson & JohnsonOct 27, 2026JNJ ▼ -1.4% - Johnson & JohnsonOct 25, 2026JNJ ▼ -1.4% - Johnson & JohnsonOct 25, 2026JNJ ▲ +1.0% - Johnson & JohnsonOct 22, 2026JNJ ▼ -0.7% - Johnson & JohnsonOct 21, 2026JNJ ▲ +0.8% - Johnson & JohnsonOct 20, 2026
View full $JNJ filing history →💬 Comments
Loading comments…
Leave a comment